Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Brief Communication
  • Basic Research
  • Published:

Effect of tumor CD276 expression on infiltrating immune cells and clinicopathological features of prostate cancer

Prostate Cancer and Prostatic Diseases (2023)Cite this article

Subjects

Abstract

Background

Advanced prostate cancer (PCa) is often resistant to immunotherapy. In this study, we examined the role of CD276 in mediating immunotherapeutic effects through changes in immune cell infiltration.

Methods

Using transcriptomic and proteomic analyses, CD276 was identified as a potential target for immunotherapy. Subsequent in vivo and in vitro experiments confirmed its role as a potential mediator of immunotherapeutic effects.

Results

Multi-omic analysis suggested that CD276 was identified as a key molecule regulating the immune microenvironment (IM). In vivo experiments revealed that CD276 knockdown was found to enhance CD8+ T cell infiltration into the IM. Immunohistochemical analysis of PCa samples further confirmed the same findings.

Conclusion

CD276 was found to inhibit the enrichment of CD8+ T cells in PCa. Thus, CD276 inhibitors may be potential targets for immunotherapy.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Identification and validation of the function of immune tumor microenvironment by vivo and vitro experiment.

Similar content being viewed by others

Data availability

All public database sources can be found in MATERIALS AND METHODS. And the Clinical data from STPH can be found in supplementary material.

References

  1. Culp MB, Soerjomataram I, Efstathiou JA, Bray F, Jemal A. Recent global patterns in prostate cancer incidence and mortality rates. Eur Urol. 2020;77:38–52.

    Article  PubMed  Google Scholar 

  2. Lee DJ, Cha EK, Dubin JM, Beltran H, Chromecki TF, Fajkovic H, et al. Novel therapeutics for the management of castration-resistant prostate cancer (CRPC). BJU Int. 2012;109:968–985.

    Article  CAS  PubMed  Google Scholar 

  3. Teo MY, Rathkopf DE, Kantoff P. Treatment of advanced prostate cancer. Annu Rev Med. 2019;70:479–499.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Zhang Y, Zhang Z. The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications. Cell Mol Immunol. 2020;17:807–821.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Majidpoor J, Mortezaee K. The efficacy of PD-1/PD-L1 blockade in cold cancers and future perspectives. Clin Immunol. 2021;226:108707.

    Article  CAS  PubMed  Google Scholar 

  6. Benzon B, Zhao SG, Haffner MC, Takhar M, Erho N, Yousefi K, et al. Correlation of B7-H3 with androgen receptor, immune pathways and poor outcome in prostate cancer: an expression-based analysis. Prostate Cancer Prostatic Dis. 2017;20:28–35.

    Article  CAS  PubMed  Google Scholar 

  7. Husain B, Martinez-Martin N. A platform for extracellular interactome discovery identifies novel functional binding partners for the immune receptors B7-H3/CD276 and PVR/CD155. Ann Oncol. 2019;30:xi37.

    Article  Google Scholar 

  8. Vigdorovich V, Ramagopal U, Lázár-Molnár E, Sylvestre E, Lee J, Hofmeyer K, et al. Structure and T cell inhibition properties of B7 family member, B7-H3. Structure 2013;21:707–717.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Mahnke K, Ring S, Johnson TS, Schallenberg S, Schönfeld K, Storn V, et al. Induction of immunosuppressive functions of dendritic cells in vivo by CD4+CD25+ regulatory T cells: role of B7-H3 expression and antigen presentation. Eur J Immunol. 2007;37:2117–2126.

    Article  CAS  PubMed  Google Scholar 

  10. Xavier FCA, Silva JC, Rodini CO, Rodrigues M. Mechanisms of immune evasion by head and neck cancer stem cells. Front Oral Health. 2022;3:957310.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Scribner JA, Brown JG, Son T, Chiechi M, Li P, Sharma S, et al. Preclinical development of MGC018, a duocarmycin-based antibody-drug conjugate targeting B7-H3 for solid cancer. Mol Cancer Ther. 2020;19:2235–2244.

    Article  CAS  PubMed  Google Scholar 

  12. Aggarwal C, Prawira A, Antonia S, Rahma O, Tolcher A, Cohen RB, et al. Dual checkpoint targeting of B7-H3 and PD-1 with enoblituzumab and pembrolizumab in advanced solid tumors: interim results from a multicenter phase I/II trial. J Immunother Cancer. 2022;10:e004424.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

We would like to thank Prof. Qiangyuan Fan for excellent technical support.

Funding

This work was supported in part by a grant from the National Natural Science Foundation of China, Youth Project (#82101838,#82203367); Experimental Animal Fund of Shanghai Science and Technology Commission, (#22140903800).

Author information

Author notes

  1. These authors contributed equally: Ji Liu, Aimaitiaji Kadier, Yadong Guo.

Authors and Affiliations

  1. Department of Urology, Shanghai Tenth People’s Hospital, School of Medicine, Tongji University, Shanghai, China

    Ji Liu, Aimaitiaji Kadier, Yadong Guo, Wentao Zhang, Haotian Chen, Zhijin Zhang, Changcheng Guo, Jiang Geng, Junfeng Zhang, Shiyu Mao & Xudong Yao

  2. Urologic Cancer Institute, School of Medicine, Tongji University, Shanghai, China

    Ji Liu, Aimaitiaji Kadier, Yadong Guo, Wentao Zhang, Haotian Chen, Zhijin Zhang, Changcheng Guo, Jiang Geng, Junfeng Zhang, Shiyu Mao & Xudong Yao

  3. Department of Central Laboratory, Clinical Medicine Scientific and Technical Innovation Park, Shanghai Tenth People’s Hospital, Shanghai, 200435, China

    Yue Zhang & Meiyu Bao

Authors
  1. Ji Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Aimaitiaji Kadier
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yadong Guo
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Wentao Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Haotian Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Zhijin Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Changcheng Guo
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Yue Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Meiyu Bao
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Jiang Geng
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Junfeng Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Shiyu Mao
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Xudong Yao
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

LJ and AJ wrote the manuscript. GYD, ZWT, and CHT collected patient data from our center. ZZJ, WH, and ZY contributed to data analysis, and BMY and GJ contributed to the in vivo experiment. MSY, ZJF, and YXD contributed ideas of the manuscript. All authors read and approved the final manuscript.

Corresponding authors

Correspondence to Junfeng Zhang, Shiyu Mao or Xudong Yao.

Ethics declarations

Competing interests

The authors declare no competing interests.

Ethics approval and consent to participate

All patients gave informed consent to the study, which was approved by the ethics committee of Shanghai Tenth People’s Hospital (No: SHSY-IEC-4.1/19-120/01).

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Liu, J., Kadier, A., Guo, Y. et al. Effect of tumor CD276 expression on infiltrating immune cells and clinicopathological features of prostate cancer. Prostate Cancer Prostatic Dis (2023). https://doi.org/10.1038/s41391-023-00690-2

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1038/s41391-023-00690-2

Search

Advanced search

Quick links